Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garrido, P; Aldaz, A; Calleja, MA; de Alava, E; Lamas, MJ; Martin, M; Matias-Guiu, X; Palacios, J; Vera, R.

Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH

FARMACIA HOSPITALARIA. 2017; 41(6): 688-691 Nº de citas: 3

Alvarez, YE; Insignares, CA; Olea, MA; Barajas, O; Calderillo, G; Guaman, JCC; Caponero, R; Salazar, BAC; del Giglio, A; Araya, ARP; Villalobos-Valencia, R; Perez, AY; Delgado, NZ.

Cancer pain management: recommendations from a Latin-American experts panel

Future Oncology. 2017; 13(27): 2455-2472 Nº de citas: 2 [doi:10.2217/fon-2017-0288]

Martin, M; Chacon, JI; Anton, A; Plazaola, A; Garcia-Martinez, E; Segui, MA; Sanchez-Rovira, P; Palacios, J; Calvo, L; Esteban, C; Espinosa, E; Barnadas, A; Batista, N; Guerrero, A; Munoz, M; Romio, E; Rodriguez-Martin, C; Caballero, R; Casas, MI; Rojo, F; Carrasco, E; Antolin, S.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis

ONCOLOGIST. 2017; 22(11): 1301-1308 Nº de citas: 14 [doi:10.1634/theoncologist.2017-0052]

Long, GV; Weber, JS; Larkin, J; Atkinson, V; Grob, JJ; Schadendorf, D; Dummer, R; Robert, C; Marquez-Rodas, I; McNeil, C; Schmidt, H; Briscoe, K; Baurain, JF; Hodi, FS; Wolchok, JD.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials

JAMA Oncology. 2017; 3(11): 1511-1519 Nº de citas: 142 [doi:10.1001/jamaoncol.2017.1588]

Marquez-Rodas, I; Pollan, M; Escudero, MJ; Ruiz, A; Martin, M; Santaballa, A; del Prado, PM; Batista, N; Andres, R; Anton, A; Llombart, A; Aramburu, AF; Adrover, E; Gonzalez, S; Segui, MA; Calvo, L; Lizon, J; Lescure, AR; Cajal, TRY; Llort, G; Jara, C; Carrasco, E; Lopez-Tarruella, S.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "ElA Alamo III" retrospective study

PLoS One. 2017; 12(10): [doi:10.1371/journal.pone.0184181]

Blagoev, KB; Wilkerson, J; Burotto, M; Kim, C; Espinal-Dominguez, E; Garcia-Alfonso, P; Alimchandani, M; Miettinen, M; Blanco-Codesido, M; Fojo, T.

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status

PLoS One. 2017; 12(10): Nº de citas: 1 [doi:10.1371/journal.pone.0175484]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, JJ; Cowey, CL; Lao, CD; Wagstaff, J; Schadendorf, D; Ferrucci, PF; Smylie, M; Dummer, R; Hill, A; Hogg, D; Haanen, J; Carlino, MS; Bechter, O; Maio, M; Marquez-Rodas, I; Guidoboni, M; McArthur, G; Lebbe, C; Ascierto, PA; Long, GV; Cebon, J; Sosman, J; Postow, MA; Callahan, MK; Walker, D; Rollin, L; Bhore, R; Hodi, FS; Larkin, J.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2017; 377(14): 1345-1356 Nº de citas: 2948 [doi:10.1056/NEJMoa1709684]

Garcia-Donas, J; Leon, LA; Esteban, E; Vidal-Mendez, MJ; Arranz, JA; del Muro, XG; Basterretxea, L; del Alba, AG; Climent, MA; Virizuela, JA; Alvarez, C; Sepulveda, J; Anido, U; Lopez, C; Ortiz-Morales, MJ; Perez, X; Rodriguez-Antona, C; Rodriguez-Moreno, JF; Hernando, S; Castellano, D.

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

European Urology Focus. 2017; 3(4-5): 430-436 Nº de citas: 5 [doi:10.1016/j.euf.2016.09.004]

Aranda, E; Aparicio, J; Bilbao, JI; Alfonso, PG; Maurel, J; Rodriguez, J; Sangro, B; Vieitez, JM; Feliu, J.

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases

Future Oncology. 2017; 13(23): 2065-2082 Nº de citas: 7 [doi:10.2217/fon-2017-0220]

Espinosa, E; Marquez-Rodas, I; Soria, A; Berrocal, A; Manzano, JL; Gonzalez-Cao, M; Martin-Algarra, S.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)

Annals of Translational Medicine. 2017; 5(19): Nº de citas: 20 [doi:10.21037/atm.2017.08.10]

Gonzalez-Cao, M; Berrocal, A; Puig, S; Karachaliou, N; De Matos-Arruda, L; Seoane, J; Escors, D; Alvarez, C; Vaque, JP; Prat, A; Wellbrock, C; Arozarena, I; Marquez-Rodas, I; Espinosa, E; Molina, MA; Puertolas, T; Juan-Otero, M; Malagrida, R; Jantus-Lewintre, E; Soriano, V; Arance, A; Manzano, JL; Lorigan, P; Gajewski, TF; Rosell, R; Martin-Algarra, S; Spanish Melanoma Grp GEM.

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

Annals of Translational Medicine. 2017; 5(19): [doi:10.21037/atm.2017.06.36]

Soria, A; Manzano, JL; Berrocal, A; Espinosa, E; Marquez-Rodas, I; Gonzalez-Cao, M; Martin-Algarra, S.

Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM)

Annals of Translational Medicine. 2017; 5(19): [doi:10.21037/atm.2017.06.37]

Lopez-Tarruella, S; Jerez, Y; Marquez-Rodas, I; Echavarria, I; Martin, M.

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer

Future Oncology. 2017; 13(24): 2137-2149 Nº de citas: 7 [doi:10.2217/fon-2017-0183]

Provencio, M; Royuela, A; Torrente, M; Pollan, M; Gomez-Codina, J; Sabin, P; Llanos, M; Guma, J; Quero, C; Blasco, A; Aguiar, D; Garcia-Arroyo, FR; Lavernia, J; Martinez, N; Morales, M; Saenz-Cusi, A; Rodriguez, D; Calvo, V; de la Cruz-Merino, L; de la Cruz, MA; Rueda, A; Spanish Lymphoma Oncology Grp.

Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group

CANCER. 2017; 123(19): 3709-3716 Nº de citas: 23 [doi:10.1002/cncr.30795]

Ocana, A; Gil-Martin, M; Martin, M; Rojo, F; Antolin, S; Guerrero, A; Trigo, JM; Munoz, M; Pandiella, A; Diego, NG; Bezares, S; Caballero, R; Carrasco, E; Urruticoechea, A.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

Oncotarget. 2017; 8(42): 73144-73153 Nº de citas: 17 [doi:10.18632/oncotarget.17113]

Fonseca, PJ; Carmona-Bayonas, A; Hernandez, R; Custodio, A; Cano, JM; Lacalle, A; Echavarria, I; Macias, I; Mangas, M; Visa, L; Buxo, E; Mancenido, FA; Viudez, A; Pericay, C; Azkarate, A; Ramchandani, A; Lopez, C; de Castro, EM; Montes, AF; Longo, F; Bayona, RS; Limon, ML; Diaz-Serrano, A; Carnicero, AM; Arias, D; Cerda, P; Rivera, F; Vieitez, JM; Canovas, MS; Garrido, M; Gallego, J; AGAMENON Study Grp.

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry

BRITISH JOURNAL OF CANCER. 2017; 117(6): 775-782 Nº de citas: 81 [doi:10.1038/bjc.2017.245]

Cohn, AL; Yoshino, T; Heinemann, V; Obermannova, R; Bodoky, G; Prausova, J; Garcia-Carbonero, R; Ciuleanu, T; Garcia-Alfonso, P; Portnoy, DC; Van Cutsem, E; Yamazaki, K; Clingan, PR; Polikoff, J; Lonardi, S; O'Brien, LM; Gao, L; Yang, L; Ferry, D; Nasroulah, F; Tabernero, J.

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2017; 80(3): 599-608 Nº de citas: 18 [doi:10.1007/s00280-017-3380-z]

Santos, C; Azuara, D; Garcia-Carbonero, R; Alfonso, PG; Carrato, A; Elez, ME; Gomez, A; Losa, F; Montagut, C; Massuti, B; Navarro, V; Varela, M; Lopez-Doriga, A; Moreno, V; Valladares, M; Manzano, JL; Vieitez, JM; Aranda, E; Sanjuan, X; Tabernero, J; Capella, G; Salazar, R.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer

MOLECULAR CANCER THERAPEUTICS. 2017; 16(9): 1999-2007 Nº de citas: 11 [doi:10.1158/1535-7163.MCT-17-0153]